

PROVIDER Update



CONTRACTUAL | SEPTEMBER 8, 2023 | UPDATE 23-1004 | 5 PAGES

Stay Current with the Injectable Medication HCPCS/DOFR Crosswalk Reference Table – 2nd Quarter 2023

Use the updates for dates of service on and after November 14, 2023

On April 11, 2023, the Health Net* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates, effective November 14, 2023, are listed on pages 2-5 of this Provider Update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- 14 new injectable medications to be added to the DOFR crosswalk.
- 22 updates and changes to injectable medication procedure codes.
- 11 updates for new generic drugs.

Additional information

Relevant sections of the Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library after logging in to the provider portal at provider.healthnetcalifornia.com > *Provider Library* under Quick Links or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the Provider Services Center by email at provider_services@healthnet.com, by phone or through the Health Net provider website as listed in the right-hand column.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer/Group
 - HMO/POS/HSP
 - EPO
 - PPO
- Wellcare By Health Net
 - Medicare Advantage (HMO)
 - Medicare Advantage (PPO)
- Medi-Cal
 - Kern
 - Los Angeles
 - Molina
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP

Ambetter PPO – 844-463-8188

Ambetter HMO – 888-926-2164

Health Net Employer Group HMO, POS,

HSP, PPO, & EPO – 800-641-7761

Medicare (individual & employer group) (Wellcare By Health Net) – 800-929-9224

Medi-Cal (including CS and ECM providers) – 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from participating physician groups (PPGs).

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
C9145	Aponvie™	Injection, aprepitant, 1 mg	Therapeutic injection	
J3590	Adstiladrin®	Gene therapy-nadofaragene firadenovec-vncg) suspension, for intravesical use	Therapeutic injection	Chemotherapy ¹
J3590	Altuviiiio™	Antihemophilic factor (recombinant) DNA-derived, factor VIII concentrate, lyophilized powder for solution, for intravenous use	Therapeutic injection	Blood/blood products for hemophilia
J3590	Briumvi™	Ublituximab-xiiy	Therapeutic injection	
C9146	Elahere™	Injection, mirvetuximab soravtansine-gynx, 1 mg, for intravenous use	Therapeutic injection	Chemotherapy ¹
J3590	Lamzede®	Velmanase alfa-tycv) for injection, for intravenous use	Therapeutic injection	
J3590	Leqembi™	Lecanemab-irmb injection, for intravenous use	Therapeutic injection	
J3590	Lunsumio™	Mosunetuzumab-axgb) injection, for intravenous use	Therapeutic injection	Chemotherapy ¹
J3490	Sezaby™	Phenobarbital injection, for intravenous use	Therapeutic injection	
J1747	Spevigo®	Injection, spesolimab-sbzo, 1 mg, for intravenous use	Therapeutic injection	
J3490	Sunlenca®	Lenacapavir injection, for subcutaneous use	Therapeutic injection	HIV/AIDS
J3490	Syfovre™	Pegcetacoplan injection, for intravitreal use	Therapeutic injection	
J0218	Xenpozyme™	Injection, olipudase alfa-rpcp, 1 mg	Therapeutic injection	
Q5129	Vegzelma®	Injection, bevacizumab-adcd, biosimilar, 10 mg	Therapeutic injection	Chemotherapy ¹

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
C9142	Alymsys®	Bevacizumab-maly injection, for intravenous use	Replaces J3590
90650	Cervarix®	Human papillomavirus bivalent (type 16 and 18) vaccine, recombinant	No longer manufactured
J2400	Chlorprocaine hcl	Chlorprocaine hcl injection	Code deleted
Q5128	Cimerli™	Injection, ranibizumab-eqrn (Cimerli), biosimilar, 0.1 mg	Replaces J3590
J3420	Cobal-1000	Vitamin B-12 cyanocobalamin, up to 1,000 mcg	No longer manufactured
Q5130	Fylnetra®	Injection, pegfilgrastim-pbbk, biosimilar, 0.5 mg	Replaces J3590
J1411	Hemgenix®	Injection, etranacogene dezaparvovec-drlb, per therapeutic dose	Replaces J7191
C9147	Imjudo®	Injection, tremelimumab-actl, 1 mg	Replaces C9999
J2325	Natrecor®	Nesiritide for injection 1.5 mg	No longer manufactured
J2506	Neulasta® Onpro® kit	Pegfilgrastim in a single-dose prefilled syringe co-packaged with the on-body injector (OBI)	Code correction
C9143	Numbrino™	Cocaine hydrochloride nasal solution, 1 mg	Reactivated
C9144	Posimir®	Bupivacaine Infiltration Solution 660 mg/5 ml (132 mg/ml)	Replaces J3490
J1449	Rolvedon™	Eflapegrastim-xnst injection, for subcutaneous use	Replaces J3490
Q5127	Stimufend®	Injection, pegfilgrastim-fpgk, biosimilar, 0.5 mg	Replaces J3590
C9148	Tecvayli™	Teclistamab-cqyv injection, for subcutaneous use	Replaces J9999
J3241	Tepezza®	Teprotumumab-trbw for injection, for intravenous use	Replaces C9061
J3420	Tia-doce s	Vitamin B-12 cyanocobalamin, up to 1,000 mcg	No longer manufactured

Updates/changes to injectable medication procedure codes or medications, *continued*

HCPCS	Drug name	Generic name	Comment
90700	Tripedia® preservative free	Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed	No longer manufactured
C9149	Tziel™	Teplizumab-mzww IV Soln 2 mg/2ml (1 mg/ml)	Replaces J3590
J9041	Velcade®	Injection, bortezomib, not otherwise specified, 0.1 mg	Replaces J9044
J1562	Vivaglobin®	Immune globulin, subcutaneous, 100 mg	No longer manufactured
Q2017	Vumon®	Teniposide, 50 mg	No longer manufactured

New generic injectable medications

The following medications have been approved by the Health Net Pharmacy and Therapeutics Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0612	Calcium gluconate	Injection, calcium gluconate (Fresenius Kabi), per 10 mg	Therapeutic injection	Home Health/Infusion ²
J0613	Calcium gluconate	Injection, calcium gluconate (WG Critical Care), per 10 mg	Therapeutic injection	Home Health/Infusion ²
J0611	Calcium gluconate	Injection, calcium gluconate (WG Critical Care), per 10 ml	Therapeutic injection	Home Health/Infusion ²
J0783	Cefepime	Cefepime hydrochloride (Baxter), not therapeutically equivalent to maxipime, 500 mg, J0703 injection	Therapeutic injection	
J2401	Chloroprocaine	Chloroprocaine hydrochloride, per 1 mg	Therapeutic injection	
J2402	COLOROTEKAL®	Chloroprocaine hydrochloride, per 1 mg	Therapeutic injection	
J0877	Daptomycin	Daptomycin (Hospira), not therapeutically equivalent to J0878, 1 mg	Therapeutic injection	Home Health/Infusion ²
J9196	Gemcitabine	Injection, gemcitabine hydrochloride (Accord), not therapeutically equivalent to J9201, 200 mg	Therapeutic injection	Chemotherapy Adjunctive ¹

New generic injectable medications, *continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9294	Pemetrexed	Injection, pemetrexed (Hospira), not therapeutically equivalent to J9305, 10 mg	Therapeutic injection	Chemotherapy Adjunctive ¹
J9296	Pemetrexed	Injection, pemetrexed (Accord), not therapeutically equivalent to J9305, 10 mg	Therapeutic injection	Chemotherapy Adjunctive ¹
J9297	Pemetrexed	Injection, pemetrexed (Sandoz), not therapeutically equivalent to J9305, 10 mg	Therapeutic injection	Chemotherapy Adjunctive ¹

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.